Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytovir-3
- Development stage
- Unknown
- Lead developer
- CytoMed Therapeutics
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
Cytovir-3 is an approved, over-the-counter combination drug developed by Cytomed for the prevention and treatment of influenza and acute respiratory viral infections (ARVI). It consists of three active components: bendazole hydrochloride (an immunomodulator and vasodilator), alpha-glutamyl-tryptophan sodium (Thymogen, a synthetic dipeptide immunomodulator), and ascorbic acid (Vitamin C, an antioxidant). Bendazole stimulates the production of endogenous interferons and inhibits phosphodiesterases, while alpha-glutamyl-tryptophan normalizes T-cell-mediated immunity by binding to DNA promoter regions and activating metabotropic glutamate receptors. Ascorbic acid acts as an antioxidant, reduces capillary permeability, and enhances humoral immunity. Together, these components provide synergistic immunostimulatory and indirect antiviral effects, reducing the severity and duration of respiratory infections.
- Brand names
- Cytovir-3Cytovir3Cytovir 3Цитовир-3
- Other names
- alpha-glutamyl-tryptophan + ascorbic acid + bendazoleascorbic acid + bendazole + sodium alpha-glutamyl-tryptophanascorbic acid + bendazole + thymogen sodium
02
Targets
PDE (Phosphodiesterase family)IFN-α (Interferon alpha-7)DNAGRM1 (Metabotropic glutamate receptor 1)
Beyond the preview
Go deeper on Cytovir-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytovir-3.